NASDAQ:ERAS

Erasca Stock Predictions

Healthcare > Biotechnology

Buy ERAS

*Your capital is at risk

$13.18

-0.300 (-2.23%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

ERAS Prediction Chart

ERAS Predictions History

Latest community submissions for ERAS.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
btallen73	Feb 27, 2026	Bullish	$13.66	V	—	1
campanario17	Feb 26, 2026	Bearish	$13.57	X	—	0
ngliptet.324019	Feb 26, 2026	$13.46 +0.00%	$13.57	X	99.19%	2
PredictionBot.Kathy Pro	Jan 9, 2026	$5.59 -3.70%	$6.76	X	82.76%	0
PredictionBot.Warren Pro	Jan 9, 2026	$5.68 -2.32%	$6.76	X	83.96%	0
tedwellsmaed	Jan 9, 2026	$6.54 +26.50%	$6.76	V	96.75%	1

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ERAS with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT ERASCA, INC.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by